Demensia Vaskular

01Pathophysiology

Vascular dementia is not a single disease but rather a heterogeneous syndrome arising from diverse cerebrovascular pathologies. The PNPK Demensia 2026 defines it as encompassing strategic single infarcts, multi-infarct dementia, cortical ischemic lesions, hemorrhagic stroke, hypoperfusion states, hypoxic injury, and mixed dementia (where Alzheimer and vascular pathology coexist). The common denominator is that ischemic or hemorrhagic damage to the brain parenchyma leads to disruption of neural circuits that subserve cognition.

The pathophysiology can be divided broadly into large vessel disease and small vessel disease. In large vessel disease, thromboembolism or cardioembolism causes cortical or strategic subcortical infarcts. A single infarct in a "strategic" location such as the thalamus, angular gyrus, or caudate nucleus can produce dementia out of proportion to lesion volume because these structures are critical hubs in memory and executive networks. Multi-infarct dementia results from the cumulative burden of repeated cortical strokes, with each event adding incremental cognitive damage, producing the classic stepwise deterioration.

In small vessel disease, chronic hypertension and diabetes cause lipohyalinosis and arteriolosclerosis of penetrating arterioles, leading to lacunar infarcts in the basal ganglia, thalamus, and internal capsule, as well as diffuse white matter ischemia (leukoaraiosis). This white matter damage disrupts frontal-subcortical circuits, which is precisely why executive dysfunction (difficulty with planning, sequencing, mental flexibility) dominates the clinical picture rather than the episodic memory deficits seen in Alzheimer disease. The PNPK Demensia 2026 also highlights CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) as a hereditary form of early-onset small vessel disease featuring extensive white matter ischemic lesions and lacunar strokes.

At the molecular level, ischemia triggers excessive glutamate release at NMDA receptors, producing excitotoxicity and neuronal death. Additionally, vascular damage impairs the cholinergic pathways that project from the basal forebrain through the white matter, resulting in a cholinergic deficit that parallels (though is mechanistically distinct from) the cholinergic loss seen in Alzheimer disease. This is the rationale for using cholinesterase inhibitors even in vascular dementia (PNPK Demensia 2026).

The concept of mixed dementia is clinically important: vascular pathology frequently coexists with Alzheimer pathology. Autopsy studies referenced in the PNPK Demensia 2026 note that vascular pathology is found in 24 to 45% of dementia cases, and cardiovascular risk factors such as hypertension, diabetes, and high LDL cholesterol accelerate neurodegenerative processes by causing cerebral vascular damage that contributes to neurodegeneration. This overlap is why controlling vascular risk factors is recommended even for patients with Alzheimer disease.

02Classification and Clinical Manifestation

Severity Staging by MMSE (PNPK Demensia 2026)

The CDR (Clinical Dementia Rating) scale is also recommended by the PNPK Demensia 2026 for staging severity, with a sensitivity of 86% and specificity of 80% for detecting MCI and early dementia.

03Diagnostic Workup

Cognitive Screening. The PNPK Demensia 2026 recommends MoCA-INA, MMSE, and CDT (Clock Drawing Test) as the front-line cognitive screening tools at referral-level health facilities. Among these, MoCA is considered superior to MMSE for detecting MCI. The validated Indonesian MoCA-INA uses a cutoff of 22/23 (sensitivity 89%, specificity 84%) rather than the Western cutoff of 26/27 due to differences in education and demographics. The MMSE optimal cutoff for detecting dementia is 23 or 24, with sensitivity and specificity both around 0.89. For informant-based screening, the AD8-INA questionnaire (score > 2 = abnormal) is recommended at the primary care level.

Neuroimaging. The PNPK Demensia 2026 explicitly states that MRI of the brain is preferred over CT because MRI has superior sensitivity for detecting vascular lesions and subtypes of dementia. A 3 Tesla MRI is preferred over 1.5 Tesla. The guideline recommends the following sequences when available: volumetric 3D T1 (with coronal reformats for hippocampal volume), FLAIR (the workhorse for white matter hyperintensities), T2, SWI (susceptibility-weighted imaging, for microbleeds), and DWI (diffusion-weighted imaging, for acute ischemia). Semiquantitative scales for routine MRI interpretation include the medial temporal lobe atrophy (MTA) scale for mesial temporal involvement, the Fazekas scale for white matter changes, and the global cortical atrophy (GCA) scale. Serial volumetric MRI can predict disease progression in vascular dementia and other subtypes.

When MRI is not available, non-contrast CT with coronal reformats is the fallback to assess hippocampal atrophy and detect old infarcts.

Establishing the Diagnosis. The diagnosis of vascular dementia per the PNPK Demensia 2026 requires: (1) documented cognitive impairment plus (2) evidence of cerebrovascular disease on neuroimaging, with (3) a clear temporal relationship between a vascular event (such as a clinical stroke) and the onset of cognitive deficits, OR a clear relationship between the severity and pattern of cognitive impairment and subcortical cerebrovascular pathology (as in small vessel disease or CADASIL), AND (4) no evidence of progressive stepwise decline before or after stroke that would suggest a non-vascular neurodegenerative process. The guideline references both the VICCCS (Vascular Impairment of Cognition Classification Consensus Study) and the CCCDTD5 (Fifth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia) as the principal diagnostic criteria frameworks.

Best Initial Test vs. Gold Standard. In practice, the best initial test is the combination of cognitive screening (MoCA-INA or MMSE) plus brain MRI with the sequences listed above. The most accurate confirmatory approach is comprehensive neuropsychological testing demonstrating a pattern of executive dysfunction plus neuroimaging evidence of cerebrovascular disease with an appropriate temporal or severity-pattern relationship. There is no single "gold standard" lab test. Definitive (pathological) confirmation requires neuropathological examination at autopsy showing cerebrovascular lesions without co-dominant neurodegenerative pathology.

04Management and Treatment

Acute Stabilization. If the patient presents with an acute stroke leading to new cognitive decline, the immediate priority is acute stroke management per standard stroke protocols (thrombolysis within the time window if ischemic, blood pressure control if hemorrhagic, ICU-level monitoring). Cognitive testing should be deferred until the patient is medically stable and delirium has been excluded.

Vascular Risk Factor Modification. The PNPK Demensia 2026 emphasizes that patients with vascular dementia who have vascular risk factors must be recommended to treat those risk factors with appropriate medications (Grade B, Level 2++). For patients with cognitive impairment where a vascular contribution is known or suspected, antihypertensive therapy should be strongly considered for average systolic BP of 140 mmHg or higher and diastolic BP of 90 mmHg or higher (Grade B, Level 1). The guideline notes that any antihypertensive class with good blood pressure-lowering efficacy can reduce dementia risk; no single class is definitively superior, though diuretics and calcium channel blockers have shown benefit in meta-analyses.

Cognitive Enhancers. The PNPK Demensia 2026 acknowledges a cholinergic deficit in vascular dementia arising from ischemia-mediated disruption of cholinergic pathways. A meta-analysis of several RCTs (n=5,183, duration 24-28 weeks) including 3 trials with donepezil, 2 with galantamine, 1 with rivastigmine, and 2 with memantine showed that all agents produced statistically significant cognitive improvement on the ADAS-cog. Among all agents tested, donepezil at 5 mg/day was the only one that achieved a positive result on the Clinical Global Impression (CGI) scale (OR 1.5, 95% CI 1.1-2.1), making it the most consistently supported option. Gastrointestinal side effects (nausea, vomiting, anorexia, weight loss) are common with AChEIs but not with memantine. The Canadian Best Practice 2019 guidelines, referenced in the PNPK, recommend that cholinesterase inhibitors and memantine can be considered for vascular dementia or mixed dementia (Grade A, Level 1).

Aspirin Nuance. Aspirin is not recommended for patients with MCI or dementia who have only covert white matter lesions on neuroimaging without a history of stroke or brain infarct (Grade C, Level 2). However, for patients with documented cerebral infarction on neuroimaging, the use of aspirin is "reasonable but benefits are unclear." This is an important point for exam purposes: do not reflexively prescribe aspirin for all vascular dementia patients.

Contraindications and Cautions. AChEIs should be used with caution in patients with sick sinus syndrome, conduction defects, active peptic ulcer disease, or asthma/COPD (due to cholinergic effects). Memantine requires dose adjustment in renal impairment (creatinine clearance < 30 mL/min). In the Indonesian Formulary (Formularium Nasional), only donepezil is listed; rivastigmine, galantamine, and memantine require special procurement mechanisms.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get vascular dementia questions wrong is by conflating it with Alzheimer disease. The vignette will plant clues: a patient with a history of hypertension, diabetes, and perhaps a prior stroke who develops executive dysfunction (trouble organizing daily tasks, impaired judgment, slowed processing) with a stepwise or abrupt decline rather than smooth, gradual memory loss. If you see these cues and still select Alzheimer disease, you have fallen into the trap. The core competency being tested is your ability to recognize the temporal pattern of decline and match the cognitive profile (executive dysfunction vs. episodic memory loss) to the correct diagnosis.

A second trap involves the imaging findings. Students see "brain atrophy on MRI" and default to Alzheimer. But the vignette will describe white matter hyperintensities (or "periventricular white matter changes"), lacunar infarcts, or microbleeds on SWI, all pointing to cerebrovascular disease. When the PNPK Demensia 2026 says MRI is preferred over CT, the reason is precisely that MRI is more sensitive for these vascular lesions.

A third pitfall is in management. Students often reflexively choose aspirin for all vascular dementia patients. Per the PNPK Demensia 2026, aspirin is not recommended for patients whose only vascular finding is covert white matter lesions without stroke history. It is reserved for secondary prevention in patients with documented stroke or brain infarct. Meanwhile, cholinesterase inhibitors (particularly donepezil) and memantine are considered appropriate for vascular dementia, a fact that surprises students who associate these drugs exclusively with Alzheimer disease.

Finally, never forget to screen for reversible contributors: medication side effects, depression, sleep apnea, hypothyroidism, and vitamin B12 deficiency. The PNPK Demensia 2026 stresses these as part of the MCI workup, and a question may present a patient with apparent vascular dementia whose cognitive decline is partly driven by a correctable metabolic or psychiatric condition. Missing the reversible cause is a classic exam error.